NDT Advance Access originally published online on February 19, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nephrol Dial Transplant (2004) 19: 1106-1115
Nephrol Dial Transplant Vol. 19 No. 5 © ERA-EDTA 2004; all rights reserved
Original Article
Pentoxifylline suppresses renal tumour necrosis factor-
and ameliorates experimental crescentic glomerulonephritis in rats
1Department of Medicine, National Taiwan University Hospital and College of Medicine National Taiwan University, 2Veterans General Hospital, Yang-Ming University, Taipei, 10016, Taiwan and 3Department of Medicine-Nephrology, Baylor College of Medicine, Houston, USA
Correspondence and offprint requests to: Dr Tun-Jun Tsai, Department of Medicine, National Taiwan University Hospital, College of Medicine National Taiwan University. No. 7, Chung-Shan South Road, Taipei, 10016, Taiwan. Email: paul{at}ha.mc.ntu.edu.tw
Background. Crescentic glomerulonephritis is a rapidly progressive form of glomerulonephritis, but treatment remains non-specific. The methylxanthine derivative pentoxifylline (PTX) is a clinically available phosphodiesterase inhibitor with anti-inflammatory and immunoregulatory activities. This study examined whether PTX has beneficial effects in a rat model of anti-glomerular basement membrane (GBM) crescentic glomerulonephritis.
Methods. Experimental crescentic glomerulonephritis was induced in Wistar rats by intravenous injection of rabbit anti-rat GBM serum and treated with either vehicle (phosphate-buffered saline) or PTX (0.1 g/kg/day) intravenously on a daily basis. Groups of six animals were euthanized at days 3, 7, 14 or 28 after induction of disease. Effects of PTX on renal function, histology and expression of cytokines, chemokines and adhesion molecules were determined.
Results. Compared with the vehicle-treated nephritic rats, PTX treatment beginning at the start of the nephritis significantly suppressed mRNA expression of tumour necrosis factor (TNF)-
, but not interleukin-1ß, throughout the course of nephritis. Moreover, PTX decreased renal mRNAs for intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), regulated on activation, normal T-cell expressed and secreted (RANTES) and osteopontin (OPN) at all time points examined. These effects were associated with a significant inhibition of macrophage and T-cell infiltration, a reduction of 24-h urinary protein excretion (5075%, P<0.05), an improvement of histological damage including glomerular crescent formation (6070%, P<0.01) and a decrease of cortical mRNAs for type I (
1) collagen and fibronectin. The efficacy of PTX could also be seen, though to a lesser extent, in rats with established nephritis.
Conclusions. PTX is an effective anti-inflammatory and immunomodulatory agent capable of suppressing rat crescentic glomerulonephritis. Inhibition of renal TNF-
, ICAM-1, RANTES, MCP-1 and OPN expression may be a mechanism whereby PTX suppresses progressive renal injury in rat crescentic glomerulonephritis.
Keywords: adhesion molecules and chemokines; crescents; glomerulonephritis; pentoxifylline; TNF-
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Lionaki, K. Siamopoulos, I. Theodorou, E. Papadimitraki, G. Bertsias, D. Boumpas, and J. Boletis Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study Nephrol. Dial. Transplant., July 1, 2009; 24(7): 2144 - 2150. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Navarro-Gonzalez and C. Mora-Fernandez The Role of Inflammatory Cytokines in Diabetic Nephropathy J. Am. Soc. Nephrol., March 1, 2008; 19(3): 433 - 442. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-L. Lin, R.-H. Chen, Y.-M. Chen, W.-C. Chiang, C.-F. Lai, K.-D. Wu, and T.-J. Tsai Pentoxifylline Attenuates Tubulointerstitial Fibrosis by Blocking Smad3/4-Activated Transcription and Profibrogenic Effects of Connective Tissue Growth Factor J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2702 - 2713. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Navarro, C. Mora, M. Muros, and J. Garcia Additive Antiproteinuric Effect of Pentoxifylline in Patients with Type 2 Diabetes under Angiotensin II Receptor Blockade: A Short-Term, Randomized, Controlled Trial J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2119 - 2126. [Abstract] [Full Text] [PDF] |
||||

